nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A4—bone cancer	0.534	1	CbGaD
Tacrolimus—MTOR—leg—bone cancer	0.00677	0.13	CbGeAlD
Tacrolimus—MTOR—forelimb—bone cancer	0.00672	0.129	CbGeAlD
Tacrolimus—MTOR—hindlimb—bone cancer	0.00605	0.116	CbGeAlD
Tacrolimus—MTOR—appendage—bone cancer	0.00519	0.0998	CbGeAlD
Tacrolimus—ORM1—vertebral column—bone cancer	0.00496	0.0953	CbGeAlD
Tacrolimus—Everolimus—CYP3A4—bone cancer	0.00207	0.306	CrCbGaD
Tacrolimus—Pimecrolimus—CYP3A4—bone cancer	0.00207	0.306	CrCbGaD
Tacrolimus—ABCA5—tendon—bone cancer	0.00204	0.0392	CbGeAlD
Tacrolimus—PPP3CA—connective tissue—bone cancer	0.002	0.0386	CbGeAlD
Tacrolimus—ABCA5—bone marrow—bone cancer	0.00198	0.038	CbGeAlD
Tacrolimus—ABCA5—spinal cord—bone cancer	0.00197	0.0378	CbGeAlD
Tacrolimus—MTOR—connective tissue—bone cancer	0.00148	0.0285	CbGeAlD
Tacrolimus—Temsirolimus—CYP3A4—bone cancer	0.0014	0.207	CrCbGaD
Tacrolimus—PPP3CA—tendon—bone cancer	0.00138	0.0265	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—bone cancer	0.00133	0.0257	CbGeAlD
Tacrolimus—FKBP1A—connective tissue—bone cancer	0.00133	0.0256	CbGeAlD
Tacrolimus—PPP3CA—spinal cord—bone cancer	0.00133	0.0256	CbGeAlD
Tacrolimus—Sirolimus—CYP3A4—bone cancer	0.00123	0.182	CrCbGaD
Tacrolimus—MTOR—tendon—bone cancer	0.00102	0.0196	CbGeAlD
Tacrolimus—MTOR—bone marrow—bone cancer	0.000986	0.019	CbGeAlD
Tacrolimus—MTOR—spinal cord—bone cancer	0.000982	0.0189	CbGeAlD
Tacrolimus—FKBP1A—tendon—bone cancer	0.000915	0.0176	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—bone cancer	0.000887	0.0171	CbGeAlD
Tacrolimus—FKBP1A—spinal cord—bone cancer	0.000883	0.017	CbGeAlD
Tacrolimus—ORM1—bone marrow—bone cancer	0.000694	0.0134	CbGeAlD
Tacrolimus—ORM1—spinal cord—bone cancer	0.000691	0.0133	CbGeAlD
Tacrolimus—ABCB1—bone marrow—bone cancer	0.000205	0.00395	CbGeAlD
Tacrolimus—ABCB1—spinal cord—bone cancer	0.000204	0.00393	CbGeAlD
Tacrolimus—MTOR—Cellular responses to stress—GSTP1—bone cancer	0.000155	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—KIT—bone cancer	0.000155	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000153	0.00153	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	0.000153	0.00153	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ENO2—bone cancer	0.000152	0.00152	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—JUN—bone cancer	0.000152	0.00151	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—JUN—bone cancer	0.000152	0.00151	CbGpPWpGaD
Tacrolimus—Conjunctivitis—Doxorubicin—bone cancer	0.000148	0.000483	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—bone cancer	0.000148	0.000482	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—bone cancer	0.000148	0.000482	CcSEcCtD
Tacrolimus—Eye disorder—Methotrexate—bone cancer	0.000148	0.000482	CcSEcCtD
Tacrolimus—Tinnitus—Methotrexate—bone cancer	0.000148	0.000481	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—bone cancer	0.000147	0.00048	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—bone cancer	0.000147	0.00147	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—BRAF—bone cancer	0.000147	0.00147	CbGpPWpGaD
Tacrolimus—Asthenia—Cisplatin—bone cancer	0.000147	0.000479	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—bone cancer	0.000147	0.000479	CcSEcCtD
Tacrolimus—Cardiac disorder—Methotrexate—bone cancer	0.000147	0.000478	CcSEcCtD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—bone cancer	0.000147	0.00147	CbGpPWpGaD
Tacrolimus—Sweating—Doxorubicin—bone cancer	0.000146	0.000477	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—bone cancer	0.000146	0.000476	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—bone cancer	0.000146	0.000475	CcSEcCtD
Tacrolimus—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000146	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	0.000146	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KIT—bone cancer	0.000146	0.00146	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KIT—bone cancer	0.000146	0.00146	CbGpPWpGaD
Tacrolimus—Haematuria—Doxorubicin—bone cancer	0.000146	0.000474	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—bone cancer	0.000146	0.000474	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—bone cancer	0.000145	0.000473	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—KIT—bone cancer	0.000144	0.00144	CbGpPWpGaD
Tacrolimus—Hepatobiliary disease—Doxorubicin—bone cancer	0.000144	0.00047	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—bone cancer	0.000144	0.000469	CcSEcCtD
Tacrolimus—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000144	0.00144	CbGpPWpGaD
Tacrolimus—Angiopathy—Methotrexate—bone cancer	0.000144	0.000468	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000144	0.00143	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—GRM1—bone cancer	0.000143	0.00143	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KIT—bone cancer	0.000143	0.00143	CbGpPWpGaD
Tacrolimus—Sinusitis—Doxorubicin—bone cancer	0.000143	0.000466	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—bone cancer	0.000143	0.000465	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—bone cancer	0.000143	0.000465	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—bone cancer	0.000143	0.000464	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—KIT—bone cancer	0.000143	0.00143	CbGpPWpGaD
Tacrolimus—Agranulocytosis—Doxorubicin—bone cancer	0.000142	0.000464	CcSEcCtD
Tacrolimus—Chills—Methotrexate—bone cancer	0.000142	0.000462	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—IL3—bone cancer	0.000142	0.00142	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—DHFR—bone cancer	0.000141	0.00141	CbGpPWpGaD
Tacrolimus—Diarrhoea—Cisplatin—bone cancer	0.00014	0.000457	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—bone cancer	0.00014	0.000456	CcSEcCtD
Tacrolimus—MTOR—AMPK Signaling—TP53—bone cancer	0.00014	0.0014	CbGpPWpGaD
Tacrolimus—Alopecia—Methotrexate—bone cancer	0.00014	0.000455	CcSEcCtD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bone cancer	0.00014	0.0014	CbGpPWpGaD
Tacrolimus—Bradycardia—Doxorubicin—bone cancer	0.000139	0.000454	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—bone cancer	0.000139	0.000452	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—bone cancer	0.000138	0.000451	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—bone cancer	0.000138	0.00045	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—bone cancer	0.000138	0.000449	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—bone cancer	0.000138	0.000449	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—MDM2—bone cancer	0.000138	0.00138	CbGpPWpGaD
Tacrolimus—Haemoglobin—Doxorubicin—bone cancer	0.000138	0.000449	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—bone cancer	0.000137	0.000448	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—bone cancer	0.000137	0.000448	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—bone cancer	0.000137	0.000447	CcSEcCtD
Tacrolimus—MTOR—Signaling by FGFR in disease—BRAF—bone cancer	0.000137	0.00137	CbGpPWpGaD
Tacrolimus—Hepatitis—Doxorubicin—bone cancer	0.000137	0.000446	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—bone cancer	0.000137	0.000446	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—bone cancer	0.000136	0.000444	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—bone cancer	0.000136	0.000443	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—bone cancer	0.000135	0.000441	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—bone cancer	0.000135	0.00044	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—KIT—bone cancer	0.000135	0.00135	CbGpPWpGaD
Tacrolimus—Dysgeusia—Methotrexate—bone cancer	0.000135	0.000439	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—bone cancer	0.000135	0.000439	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—bone cancer	0.000134	0.000438	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—bone cancer	0.000134	0.000437	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—bone cancer	0.000134	0.000436	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—bone cancer	0.000133	0.000435	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—bone cancer	0.000133	0.000434	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—ATF1—bone cancer	0.000133	0.00133	CbGpPWpGaD
Tacrolimus—Chills—Epirubicin—bone cancer	0.000133	0.000433	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—bone cancer	0.000132	0.000431	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—bone cancer	0.000132	0.00043	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—MDM2—bone cancer	0.000132	0.00132	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000131	0.00131	CbGpPWpGaD
Tacrolimus—Alopecia—Epirubicin—bone cancer	0.000131	0.000426	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00013	0.0013	CbGpPWpGaD
Tacrolimus—Vomiting—Cisplatin—bone cancer	0.00013	0.000424	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—KIT—bone cancer	0.00013	0.0013	CbGpPWpGaD
Tacrolimus—Vision blurred—Methotrexate—bone cancer	0.00013	0.000423	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—bone cancer	0.00013	0.000423	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—MDM2—bone cancer	0.00013	0.0013	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL3—bone cancer	0.00013	0.0013	CbGpPWpGaD
Tacrolimus—Erythema multiforme—Doxorubicin—bone cancer	0.00013	0.000422	CcSEcCtD
Tacrolimus—Rash—Cisplatin—bone cancer	0.000129	0.000421	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000129	0.00129	CbGpPWpGaD
Tacrolimus—Dermatitis—Cisplatin—bone cancer	0.000129	0.00042	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—bone cancer	0.000129	0.00042	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—bone cancer	0.000129	0.00042	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—GRM4—bone cancer	0.000128	0.00128	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RGS1—bone cancer	0.000128	0.00128	CbGpPWpGaD
Tacrolimus—Eye disorder—Doxorubicin—bone cancer	0.000128	0.000417	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—bone cancer	0.000128	0.000416	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—bone cancer	0.000128	0.000416	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—bone cancer	0.000127	0.000415	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—bone cancer	0.000127	0.000414	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—bone cancer	0.000127	0.000414	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—bone cancer	0.000127	0.000414	CcSEcCtD
Tacrolimus—Tension—Epirubicin—bone cancer	0.000126	0.000412	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—bone cancer	0.000126	0.000411	CcSEcCtD
Tacrolimus—MTOR—PI-3K cascade—EGFR—bone cancer	0.000126	0.00126	CbGpPWpGaD
Tacrolimus—Nervousness—Epirubicin—bone cancer	0.000125	0.000408	CcSEcCtD
Tacrolimus—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000125	0.00125	CbGpPWpGaD
Tacrolimus—Back pain—Epirubicin—bone cancer	0.000125	0.000406	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—bone cancer	0.000124	0.000405	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—bone cancer	0.000124	0.000405	CcSEcCtD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000124	0.00124	CbGpPWpGaD
Tacrolimus—Muscle spasms—Epirubicin—bone cancer	0.000124	0.000404	CcSEcCtD
Tacrolimus—MTOR—Downstream signal transduction—MDM2—bone cancer	0.000124	0.00124	CbGpPWpGaD
Tacrolimus—Immune system disorder—Doxorubicin—bone cancer	0.000124	0.000403	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—bone cancer	0.000124	0.000403	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—bone cancer	0.000123	0.000402	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—bone cancer	0.000123	0.000402	CcSEcCtD
Tacrolimus—MTOR—Signaling by FGFR—MDM2—bone cancer	0.000123	0.00123	CbGpPWpGaD
Tacrolimus—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000123	0.00123	CbGpPWpGaD
Tacrolimus—Chills—Doxorubicin—bone cancer	0.000123	0.0004	CcSEcCtD
Tacrolimus—MTOR—PI3K/AKT activation—EGFR—bone cancer	0.000123	0.00123	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—MDM2—bone cancer	0.000123	0.00123	CbGpPWpGaD
Tacrolimus—Arrhythmia—Doxorubicin—bone cancer	0.000122	0.000399	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—MDM2—bone cancer	0.000122	0.00122	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000122	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—EGFR—bone cancer	0.000122	0.00122	CbGpPWpGaD
Tacrolimus—Nausea—Cisplatin—bone cancer	0.000122	0.000396	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—bone cancer	0.000121	0.000396	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000121	0.00121	CbGpPWpGaD
Tacrolimus—Alopecia—Doxorubicin—bone cancer	0.000121	0.000394	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000121	0.00121	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	0.00012	0.0012	CbGpPWpGaD
Tacrolimus—Cough—Methotrexate—bone cancer	0.00012	0.000391	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—bone cancer	0.00012	0.000391	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—bone cancer	0.00012	0.00039	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—bone cancer	0.000119	0.000389	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—bone cancer	0.000119	0.000388	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—bone cancer	0.000119	0.000388	CcSEcCtD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	0.000119	0.00119	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—EGFR—bone cancer	0.000119	0.00119	CbGpPWpGaD
Tacrolimus—Anaemia—Epirubicin—bone cancer	0.000119	0.000388	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—bone cancer	0.000118	0.000386	CcSEcCtD
Tacrolimus—FKBP1A—Disease—ENO2—bone cancer	0.000118	0.00118	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—JUN—bone cancer	0.000118	0.00118	CbGpPWpGaD
Tacrolimus—Flatulence—Doxorubicin—bone cancer	0.000118	0.000383	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—bone cancer	0.000117	0.000382	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—bone cancer	0.000117	0.000382	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—bone cancer	0.000117	0.000382	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—bone cancer	0.000117	0.000381	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—bone cancer	0.000117	0.00038	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—MMP9—bone cancer	0.000116	0.00116	CbGpPWpGaD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000116	0.000379	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—bone cancer	0.000116	0.000379	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—bone cancer	0.000116	0.000377	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—bone cancer	0.000116	0.000377	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—bone cancer	0.000116	0.000377	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—bone cancer	0.000116	0.000377	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—bone cancer	0.000115	0.000376	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—bone cancer	0.000115	0.000376	CcSEcCtD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000115	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—MDM2—bone cancer	0.000115	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—MDM2—bone cancer	0.000115	0.00115	CbGpPWpGaD
Tacrolimus—Muscle spasms—Doxorubicin—bone cancer	0.000115	0.000373	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—bone cancer	0.000114	0.000371	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—MDM2—bone cancer	0.000114	0.00114	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000113	0.00113	CbGpPWpGaD
Tacrolimus—Confusional state—Methotrexate—bone cancer	0.000113	0.000369	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000113	0.00113	CbGpPWpGaD
Tacrolimus—Loss of consciousness—Epirubicin—bone cancer	0.000113	0.000369	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000113	0.00113	CbGpPWpGaD
Tacrolimus—Cough—Epirubicin—bone cancer	0.000112	0.000366	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—CDK4—bone cancer	0.000112	0.00112	CbGpPWpGaD
Tacrolimus—Anaphylactic shock—Methotrexate—bone cancer	0.000112	0.000366	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—bone cancer	0.000112	0.000366	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—MDM2—bone cancer	0.000112	0.00112	CbGpPWpGaD
Tacrolimus—Convulsion—Epirubicin—bone cancer	0.000112	0.000364	CcSEcCtD
Tacrolimus—Infection—Methotrexate—bone cancer	0.000112	0.000364	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—bone cancer	0.000111	0.000362	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—GRM1—bone cancer	0.000111	0.00111	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000111	0.00111	CbGpPWpGaD
Tacrolimus—Ill-defined disorder—Doxorubicin—bone cancer	0.000111	0.00036	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—bone cancer	0.00011	0.000359	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—bone cancer	0.00011	0.000359	CcSEcCtD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.00011	0.0011	CbGpPWpGaD
Tacrolimus—Thrombocytopenia—Methotrexate—bone cancer	0.00011	0.000358	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—bone cancer	0.00011	0.000357	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—bone cancer	0.00011	0.000357	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—bone cancer	0.00011	0.000357	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—bone cancer	0.00011	0.000357	CcSEcCtD
Tacrolimus—FKBP1A—Disease—DHFR—bone cancer	0.00011	0.00109	CbGpPWpGaD
Tacrolimus—Anxiety—Epirubicin—bone cancer	0.000109	0.000356	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—bone cancer	0.000109	0.000356	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000109	0.000355	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—bone cancer	0.000109	0.000354	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—bone cancer	0.000108	0.000353	CcSEcCtD
Tacrolimus—MTOR—Insulin Signaling—JUN—bone cancer	0.000108	0.00108	CbGpPWpGaD
Tacrolimus—Malaise—Doxorubicin—bone cancer	0.000108	0.00035	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—bone cancer	0.000107	0.00035	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—bone cancer	0.000107	0.000349	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—bone cancer	0.000107	0.000349	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000107	0.00107	CbGpPWpGaD
Tacrolimus—Syncope—Doxorubicin—bone cancer	0.000107	0.000348	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—bone cancer	0.000107	0.000348	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—MDM2—bone cancer	0.000106	0.00106	CbGpPWpGaD
Tacrolimus—Confusional state—Epirubicin—bone cancer	0.000106	0.000345	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—bone cancer	0.000105	0.000343	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—bone cancer	0.000105	0.000343	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—bone cancer	0.000105	0.000343	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—bone cancer	0.000105	0.000342	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—bone cancer	0.000105	0.000341	CcSEcCtD
Tacrolimus—Infection—Epirubicin—bone cancer	0.000105	0.00034	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—bone cancer	0.000104	0.000339	CcSEcCtD
Tacrolimus—Shock—Epirubicin—bone cancer	0.000104	0.000337	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—bone cancer	0.000103	0.000337	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—bone cancer	0.000103	0.000336	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—bone cancer	0.000103	0.000335	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—bone cancer	0.000103	0.000335	CcSEcCtD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000103	0.00103	CbGpPWpGaD
Tacrolimus—Tachycardia—Epirubicin—bone cancer	0.000103	0.000334	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000102	0.000334	CcSEcCtD
Tacrolimus—PPP3CA—Disease—TGFBR2—bone cancer	0.000102	0.00102	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—MDM2—bone cancer	0.000102	0.00102	CbGpPWpGaD
Tacrolimus—Skin disorder—Epirubicin—bone cancer	0.000102	0.000333	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—bone cancer	0.000102	0.000331	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000102	0.00102	CbGpPWpGaD
Tacrolimus—Insomnia—Methotrexate—bone cancer	0.000102	0.000331	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—bone cancer	0.000102	0.000331	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—bone cancer	0.000102	0.000331	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—bone cancer	0.000102	0.000331	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000101	0.00101	CbGpPWpGaD
Tacrolimus—Anxiety—Doxorubicin—bone cancer	0.000101	0.00033	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—SMO—bone cancer	0.000101	0.00101	CbGpPWpGaD
Tacrolimus—Paraesthesia—Methotrexate—bone cancer	0.000101	0.000329	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000101	0.000328	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—bone cancer	0.0001	0.000327	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—bone cancer	0.0001	0.000327	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—bone cancer	0.0001	0.000326	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—NT5C3A—bone cancer	0.0001	0.001	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bone cancer	0.0001	0.001	CbGpPWpGaD
Tacrolimus—Somnolence—Methotrexate—bone cancer	9.99e-05	0.000326	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.98e-05	0.000998	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	9.98e-05	0.000998	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ATF1—bone cancer	9.95e-05	0.000995	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KIT—bone cancer	9.93e-05	0.000993	CbGpPWpGaD
Tacrolimus—Dry mouth—Doxorubicin—bone cancer	9.93e-05	0.000323	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—bone cancer	9.9e-05	0.000322	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—bone cancer	9.83e-05	0.00032	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—bone cancer	9.82e-05	0.00032	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—RB1—bone cancer	9.78e-05	0.000978	CbGpPWpGaD
Tacrolimus—Decreased appetite—Methotrexate—bone cancer	9.77e-05	0.000318	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—bone cancer	9.73e-05	0.000317	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—bone cancer	9.73e-05	0.000317	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—bone cancer	9.71e-05	0.000316	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—bone cancer	9.69e-05	0.000316	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—bone cancer	9.67e-05	0.000315	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.63e-05	0.000962	CbGpPWpGaD
Tacrolimus—Pain—Methotrexate—bone cancer	9.61e-05	0.000313	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—bone cancer	9.58e-05	0.000312	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—bone cancer	9.58e-05	0.000312	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—bone cancer	9.55e-05	0.000311	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—bone cancer	9.53e-05	0.00031	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—bone cancer	9.52e-05	0.00031	CcSEcCtD
Tacrolimus—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	9.51e-05	0.000951	CbGpPWpGaD
Tacrolimus—Tachycardia—Doxorubicin—bone cancer	9.5e-05	0.000309	CcSEcCtD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.46e-05	0.000945	CbGpPWpGaD
Tacrolimus—Skin disorder—Doxorubicin—bone cancer	9.46e-05	0.000308	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—bone cancer	9.45e-05	0.000308	CcSEcCtD
Tacrolimus—MTOR—Signaling by SCF-KIT—EGFR—bone cancer	9.41e-05	0.000941	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Doxorubicin—bone cancer	9.41e-05	0.000306	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—bone cancer	9.38e-05	0.000305	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—bone cancer	9.35e-05	0.000305	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—BRAF—bone cancer	9.34e-05	0.000933	CbGpPWpGaD
Tacrolimus—Anorexia—Doxorubicin—bone cancer	9.28e-05	0.000302	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—bone cancer	9.26e-05	0.000302	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—bone cancer	9.26e-05	0.000302	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—GNA11—bone cancer	9.25e-05	0.000924	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Methotrexate—bone cancer	9.19e-05	0.000299	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—bone cancer	9.15e-05	0.000298	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—bone cancer	9.1e-05	0.000296	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—bone cancer	9.08e-05	0.000296	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—bone cancer	9.07e-05	0.000295	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bone cancer	9.01e-05	0.0009	CbGpPWpGaD
Tacrolimus—Pain—Epirubicin—bone cancer	9e-05	0.000293	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—bone cancer	9e-05	0.000293	CcSEcCtD
Tacrolimus—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.95e-05	0.000895	CbGpPWpGaD
Tacrolimus—Urticaria—Methotrexate—bone cancer	8.93e-05	0.000291	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bone cancer	8.91e-05	0.000891	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—JUN—bone cancer	8.89e-05	0.000889	CbGpPWpGaD
Tacrolimus—Abdominal pain—Methotrexate—bone cancer	8.89e-05	0.000289	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—bone cancer	8.89e-05	0.000289	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.87e-05	0.000289	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—EGFR—bone cancer	8.86e-05	0.000886	CbGpPWpGaD
Tacrolimus—Insomnia—Doxorubicin—bone cancer	8.8e-05	0.000287	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—NDUFA12—bone cancer	8.74e-05	0.000874	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—bone cancer	8.74e-05	0.000285	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—bone cancer	8.68e-05	0.000283	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—bone cancer	8.67e-05	0.000282	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—bone cancer	8.65e-05	0.000282	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—bone cancer	8.6e-05	0.00028	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—ATF1—bone cancer	8.59e-05	0.000859	CbGpPWpGaD
Tacrolimus—Dyspepsia—Doxorubicin—bone cancer	8.57e-05	0.000279	CcSEcCtD
Tacrolimus—MTOR—Downstream signal transduction—EGFR—bone cancer	8.46e-05	0.000846	CbGpPWpGaD
Tacrolimus—Decreased appetite—Doxorubicin—bone cancer	8.46e-05	0.000276	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.46e-05	0.000845	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.44e-05	0.000843	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—EGFR—bone cancer	8.42e-05	0.000842	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bone cancer	8.42e-05	0.000842	CbGpPWpGaD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—bone cancer	8.4e-05	0.000274	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—bone cancer	8.39e-05	0.000273	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—IL3—bone cancer	8.38e-05	0.000838	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—EGFR—bone cancer	8.38e-05	0.000838	CbGpPWpGaD
Tacrolimus—Urticaria—Epirubicin—bone cancer	8.36e-05	0.000272	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—EGFR—bone cancer	8.34e-05	0.000834	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—MDM2—bone cancer	8.34e-05	0.000833	CbGpPWpGaD
Tacrolimus—Constipation—Doxorubicin—bone cancer	8.32e-05	0.000271	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—bone cancer	8.32e-05	0.000271	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—bone cancer	8.32e-05	0.000271	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—bone cancer	8.32e-05	0.000271	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.31e-05	0.000831	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Methotrexate—bone cancer	8.28e-05	0.00027	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	8.22e-05	0.000822	CbGpPWpGaD
Tacrolimus—Asthenia—Methotrexate—bone cancer	8.07e-05	0.000263	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—bone cancer	8.02e-05	0.000261	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—bone cancer	7.96e-05	0.000259	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—bone cancer	7.95e-05	0.000259	CcSEcCtD
Tacrolimus—FKBP1A—Disease—TGFBR2—bone cancer	7.94e-05	0.000793	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—EGFR—bone cancer	7.85e-05	0.000784	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	7.85e-05	0.000784	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—EGFR—bone cancer	7.85e-05	0.000784	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SMO—bone cancer	7.84e-05	0.000783	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—MDM2—bone cancer	7.82e-05	0.000782	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—EGFR—bone cancer	7.78e-05	0.000777	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Epirubicin—bone cancer	7.75e-05	0.000252	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—bone cancer	7.73e-05	0.000252	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bone cancer	7.71e-05	0.00077	CbGpPWpGaD
Tacrolimus—Body temperature increased—Doxorubicin—bone cancer	7.7e-05	0.000251	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—bone cancer	7.7e-05	0.000251	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—bone cancer	7.69e-05	0.000251	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—EGFR—bone cancer	7.67e-05	0.000767	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KIT—bone cancer	7.57e-05	0.000756	CbGpPWpGaD
Tacrolimus—Asthenia—Epirubicin—bone cancer	7.55e-05	0.000246	CcSEcCtD
Tacrolimus—ALB—Metabolism—NDUFA12—bone cancer	7.53e-05	0.000752	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bone cancer	7.48e-05	0.000748	CbGpPWpGaD
Tacrolimus—Pruritus—Epirubicin—bone cancer	7.44e-05	0.000242	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—bone cancer	7.43e-05	0.000242	CcSEcCtD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.28e-05	0.000728	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—EGFR—bone cancer	7.26e-05	0.000726	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—JUN—bone cancer	7.25e-05	0.000724	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NT5C3A—bone cancer	7.24e-05	0.000724	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RGS1—bone cancer	7.22e-05	0.000721	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GRM4—bone cancer	7.22e-05	0.000721	CbGpPWpGaD
Tacrolimus—Diarrhoea—Epirubicin—bone cancer	7.2e-05	0.000234	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—bone cancer	7.17e-05	0.000234	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—GNA11—bone cancer	7.17e-05	0.000716	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFBR2—bone cancer	7.17e-05	0.000716	CbGpPWpGaD
Tacrolimus—Vomiting—Methotrexate—bone cancer	7.15e-05	0.000233	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—TP53—bone cancer	7.13e-05	0.000712	CbGpPWpGaD
Tacrolimus—Rash—Methotrexate—bone cancer	7.09e-05	0.000231	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—bone cancer	7.08e-05	0.000231	CcSEcCtD
Tacrolimus—Headache—Methotrexate—bone cancer	7.04e-05	0.000229	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—EGFR—bone cancer	6.99e-05	0.000699	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KIT—bone cancer	6.99e-05	0.000698	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—bone cancer	6.98e-05	0.000227	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—bone cancer	6.96e-05	0.000227	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	6.95e-05	0.000695	CbGpPWpGaD
Tacrolimus—Pruritus—Doxorubicin—bone cancer	6.89e-05	0.000224	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—IGF1R—bone cancer	6.74e-05	0.000674	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—bone cancer	6.69e-05	0.000218	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—bone cancer	6.68e-05	0.000217	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—ATF1—bone cancer	6.66e-05	0.000666	CbGpPWpGaD
Tacrolimus—Diarrhoea—Doxorubicin—bone cancer	6.66e-05	0.000217	CcSEcCtD
Tacrolimus—MTOR—Disease—ENO2—bone cancer	6.64e-05	0.000664	CbGpPWpGaD
Tacrolimus—Rash—Epirubicin—bone cancer	6.63e-05	0.000216	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—bone cancer	6.63e-05	0.000216	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—NDUFA12—bone cancer	6.6e-05	0.000659	CbGpPWpGaD
Tacrolimus—Headache—Epirubicin—bone cancer	6.59e-05	0.000215	CcSEcCtD
Tacrolimus—PPP3CA—Disease—BRAF—bone cancer	6.57e-05	0.000656	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL3—bone cancer	6.5e-05	0.00065	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—bone cancer	6.44e-05	0.00021	CcSEcCtD
Tacrolimus—ALB—Hemostasis—SPARC—bone cancer	6.39e-05	0.000639	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.27e-05	0.000627	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GRM1—bone cancer	6.26e-05	0.000625	CbGpPWpGaD
Tacrolimus—Nausea—Epirubicin—bone cancer	6.25e-05	0.000204	CcSEcCtD
Tacrolimus—ALB—Metabolism—NT5C3A—bone cancer	6.24e-05	0.000623	CbGpPWpGaD
Tacrolimus—Vomiting—Doxorubicin—bone cancer	6.19e-05	0.000202	CcSEcCtD
Tacrolimus—MTOR—Disease—DHFR—bone cancer	6.16e-05	0.000616	CbGpPWpGaD
Tacrolimus—Rash—Doxorubicin—bone cancer	6.14e-05	0.0002	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—bone cancer	6.13e-05	0.0002	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—bone cancer	6.1e-05	0.000199	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—MDM2—bone cancer	5.96e-05	0.000596	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—GNA11—bone cancer	5.84e-05	0.000584	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.8e-05	0.00058	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ATF1—bone cancer	5.8e-05	0.000579	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—bone cancer	5.78e-05	0.000188	CcSEcCtD
Tacrolimus—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.72e-05	0.000572	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KIT—bone cancer	5.66e-05	0.000566	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL3—bone cancer	5.65e-05	0.000565	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFBR2—bone cancer	5.56e-05	0.000556	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MDM2—bone cancer	5.5e-05	0.00055	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NT5C3A—bone cancer	5.47e-05	0.000546	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KIT—bone cancer	5.44e-05	0.000544	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KIT—bone cancer	5.42e-05	0.000541	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—EGFR—bone cancer	5.35e-05	0.000534	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—bone cancer	5.3e-05	0.00053	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL3—bone cancer	5.3e-05	0.000529	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IGF1R—bone cancer	5.23e-05	0.000523	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—JUN—bone cancer	5.18e-05	0.000518	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—BRAF—bone cancer	5.09e-05	0.000509	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KIT—bone cancer	4.89e-05	0.000489	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—bone cancer	4.78e-05	0.000478	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.65e-05	0.000465	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—BRAF—bone cancer	4.6e-05	0.00046	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.48e-05	0.000448	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFBR2—bone cancer	4.46e-05	0.000446	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MDM2—bone cancer	4.46e-05	0.000446	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—EGFR—bone cancer	4.46e-05	0.000445	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMO—bone cancer	4.41e-05	0.000441	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ENO2—bone cancer	4.39e-05	0.000439	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—MDM2—bone cancer	4.28e-05	0.000428	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MDM2—bone cancer	4.27e-05	0.000426	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—bone cancer	4.11e-05	0.000411	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—EGFR—bone cancer	4.07e-05	0.000407	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—DHFR—bone cancer	4.07e-05	0.000407	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NDUFA12—bone cancer	4.06e-05	0.000406	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.04e-05	0.000404	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GNA11—bone cancer	4.03e-05	0.000403	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—JUN—bone cancer	3.88e-05	0.000388	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MDM2—bone cancer	3.85e-05	0.000385	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GNA11—bone cancer	3.81e-05	0.00038	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KIT—bone cancer	3.79e-05	0.000379	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—EGFR—bone cancer	3.76e-05	0.000376	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ATF1—bone cancer	3.75e-05	0.000375	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL3—bone cancer	3.66e-05	0.000365	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—BRAF—bone cancer	3.57e-05	0.000356	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PLAU—bone cancer	3.47e-05	0.000347	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CYP3A4—bone cancer	3.45e-05	0.000345	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NT5C3A—bone cancer	3.37e-05	0.000337	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—JUN—bone cancer	3.35e-05	0.000335	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIT—bone cancer	3.3e-05	0.00033	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—bone cancer	3.26e-05	0.000326	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.18e-05	0.000318	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ENO2—bone cancer	3.17e-05	0.000317	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFBR2—bone cancer	3.13e-05	0.000312	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—bone cancer	3.05e-05	0.000305	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KIT—bone cancer	3.05e-05	0.000304	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MDM2—bone cancer	2.99e-05	0.000299	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTP1—bone cancer	2.95e-05	0.000295	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DHFR—bone cancer	2.94e-05	0.000294	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1R—bone cancer	2.94e-05	0.000294	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—bone cancer	2.93e-05	0.000293	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—bone cancer	2.92e-05	0.000291	CbGpPWpGaD
Tacrolimus—MTOR—Disease—BRAF—bone cancer	2.86e-05	0.000286	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNA11—bone cancer	2.75e-05	0.000275	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ENO2—bone cancer	2.73e-05	0.000273	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.67e-05	0.000267	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—bone cancer	2.63e-05	0.000263	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—MDM2—bone cancer	2.6e-05	0.00026	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—JUN—bone cancer	2.6e-05	0.00026	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DHFR—bone cancer	2.53e-05	0.000253	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—bone cancer	2.53e-05	0.000252	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000249	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MDM2—bone cancer	2.4e-05	0.00024	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—bone cancer	2.39e-05	0.000239	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNA11—bone cancer	2.37e-05	0.000237	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—bone cancer	2.31e-05	0.000231	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JUN—bone cancer	2.26e-05	0.000226	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DHFR—bone cancer	2.22e-05	0.000222	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—bone cancer	2.21e-05	0.000221	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP3A4—bone cancer	2.15e-05	0.000215	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.14e-05	0.000214	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—bone cancer	2.13e-05	0.000213	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—bone cancer	2.13e-05	0.000213	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNA11—bone cancer	2.08e-05	0.000207	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—bone cancer	2.04e-05	0.000204	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—BRAF—bone cancer	2.01e-05	0.0002	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000188	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—bone cancer	1.84e-05	0.000184	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—bone cancer	1.78e-05	0.000177	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—bone cancer	1.71e-05	0.000171	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—bone cancer	1.68e-05	0.000168	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—bone cancer	1.64e-05	0.000164	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—bone cancer	1.61e-05	0.000161	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—bone cancer	1.53e-05	0.000153	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—bone cancer	1.47e-05	0.000147	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JUN—bone cancer	1.46e-05	0.000146	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—bone cancer	1.42e-05	0.000142	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—bone cancer	1.4e-05	0.00014	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DHFR—bone cancer	1.37e-05	0.000137	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNA11—bone cancer	1.28e-05	0.000128	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—bone cancer	1.15e-05	0.000115	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—bone cancer	1.11e-05	0.00011	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—bone cancer	9.92e-06	9.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—bone cancer	9.64e-06	9.63e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—bone cancer	9.52e-06	9.51e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—bone cancer	8.34e-06	8.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—bone cancer	5.14e-06	5.13e-05	CbGpPWpGaD
